InsiderTrades

Form 4 for AMGN Amgen

Accepted 2022-05-04 00:00:00 ET · period of report 2022-05-02 · accession 0001127602-22-013339 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-05-04 2022-05-03 AMGN Bradway Robert A COB, CEO, Pres, Dir F - Tax $230.92 -2,692 621.9K -0.4% -$621.6K
D 2022-05-04 2022-05-02 AMGN Bradway Robert A COB, CEO, Pres, Dir A - Grant $0.00 +13.8K 624.5K +2% $0
D 2022-05-04 2022-05-02 AMGN Bradway Robert A COB, CEO, Pres, Dir A - Grant $0.00 +112.5K 112.5K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-05-03 F D 2,692 $230.92 621,858 D — — (F3) These shares include 1,688 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. (F2) These shares include the following RSUs granted under the Company's equity plans: 5,369 RSUs which will vest in an installment of 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025; and 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2 Common Common Stock 2022-05-02 A A 13,781 $0.00 624,550 D — — (F1) The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.
3 Derivative Nqso (Right to Buy) 2022-05-02 A A 112,508 $0.00 112,508 D $230.92 · 2024-05-02 to 2032-05-02 112,508 Common Stock (F4) These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively